research use only

Phospho-ErbB3/HER3 (Tyr1289) Antibody [P19F5]

Cat.No.: F3001

Application: Reactivity: Human

Usage Information

Dilution
WB1:2500 - 1:5000 IF1:100

Application
WB, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
148 kDa 185 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Phospho-ErbB3/HER3 (Tyr1289) Antibody [P19F5] detects endogenous levels of total HER3/ErbB3 protein only when it is phosphorylated at Tyr1289.

Clone
P19F5

Synonym(s)
HER3; ERBB3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor HER3

Background
Phospho-ErbB3/HER3 (Tyr1289), the tyrosine-phosphorylated form at residue 1289 of the kinase-impaired ErbB3 receptor (a 185 kDa member of the EGFR/ErbB family with an extracellular ligand-binding domain, single-span transmembrane helix, catalytically inactive juxtamembrane/intracellular kinase domain featuring a disrupted ATP-binding pocket, and a C-terminal tail harboring at least nine phospho-tyrosines including the YXXM motif at Tyr1289), emerges upon ligand-induced (neuregulin) heterodimerization with active ErbB partners like EGFR/ErbB1 or HER2/ErbB2, where the partner's kinase phosphorylates ErbB3 in trans, triggering a conformational shift that exposes the pTyr1289 docking site for the p85 regulatory subunit of PI3K to initiate robust PI3K/AKT/mTOR signaling for cell survival, proliferation, and migration, while also recruiting Grb2/Sos for parallel MAPK/ERK activation and Src family kinases for crosstalk, distinct from other sites like Tyr1222, pTyr1289 uniquely drives high-affinity PI3K binding due to its YXXM sequence, amplifying oncogenic signaling in heterodimers without ErbB3's own kinase activity. This phosphorylation sustains rapid receptor recycling/trafficking, sustains autocrine loops in tumors, and resists apoptosis, with overexpression/hyperactivation prevalent in breast, lung, ovarian, and head/neck cancers, where ErbB2-ErbB3 dimers fuel therapy resistance, invasion/metastasis via EMT, and poor prognosis.

Background

Phospho-ErbB3/HER3 (Tyr1289), the tyrosine-phosphorylated form at residue 1289 of the kinase-impaired ErbB3 receptor (a 185 kDa member of the EGFR/ErbB family with an extracellular ligand-binding domain, single-span transmembrane helix, catalytically inactive juxtamembrane/intracellular kinase domain featuring a disrupted ATP-binding pocket, and a C-terminal tail harboring at least nine phospho-tyrosines including the YXXM motif at Tyr1289), emerges upon ligand-induced (neuregulin) heterodimerization with active ErbB partners like EGFR/ErbB1 or HER2/ErbB2, where the partner's kinase phosphorylates ErbB3 in trans, triggering a conformational shift that exposes the pTyr1289 docking site for the p85 regulatory subunit of PI3K to initiate robust PI3K/AKT/mTOR signaling for cell survival, proliferation, and migration, while also recruiting Grb2/Sos for parallel MAPK/ERK activation and Src family kinases for crosstalk, distinct from other sites like Tyr1222, pTyr1289 uniquely drives high-affinity PI3K binding due to its YXXM sequence, amplifying oncogenic signaling in heterodimers without ErbB3's own kinase activity. This phosphorylation sustains rapid receptor recycling/trafficking, sustains autocrine loops in tumors, and resists apoptosis, with overexpression/hyperactivation prevalent in breast, lung, ovarian, and head/neck cancers, where ErbB2-ErbB3 dimers fuel therapy resistance, invasion/metastasis via EMT, and poor prognosis.

References
https://pubmed.ncbi.nlm.nih.gov/31351986/ https://pubmed.ncbi.nlm.nih.gov/22733765/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%